Green tea extract studied as possible IPF treatment

NCT ID NCT05195918

Completed Symptom relief Sponsor: Hal Chapman Source: ClinicalTrials.gov ↗

First seen Jan 26, 2026 · Last updated May 20, 2026 · Updated 15 times

Summary

This study tested the safety of a purified green tea extract called EGCG in 50 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. Participants took EGCG or a placebo daily for 12 weeks. The main goal was to see if EGCG is safe and how it interacts with standard IPF medications. This is an early-stage study, so it focuses on safety and side effects, not on curing the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Temple University

Philadelphia, Pennsylvania, 19140, United States
UCSF Parnassus

San Francisco, California, 94143, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Virginia

Charlottesville, Virginia, 22908, United States
University of Washington

Seattle, Washington, 98195, United States
Weill Cornell Medicine

New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.

IDIOPATHIC PULMONARY FIBROSIS